Nuwellis, Inc. (NUWE)
Oxford Ledge is still expanding full research coverage of NUWE. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Nuwellis makes ultrafiltration devices to treat fluid overload in heart failure and kidney disease patients unresponsive to diuretics.
SEC filings
- DEF 14A Proxy statement for shareholder vote 2026-07-07
- 8-K 3.03; Amendments to articles or bylaws; Financial statements and exhibits 2026-06-24
- 8-K Departure/election of directors or officers; Regulation FD disclosure; Financial statements and exhibits 2026-06-18
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-10
- S-1/A Amended registration statement 2026-06-04
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for NUWE. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open NUWE in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.